Study of a new pill for psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study tests an investigational medication (zasocitinib) taken by mouth to reduce joint pain, swelling, and skin symptoms in adults with psoriatic arthritis. It is for people whose symptoms have not improved enough with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of psoriatic arthritis, with symptoms for at least 3 months.
- You have at least 3 tender and 3 swollen joints, and some joint damage visible on x-rays.
- You have at least one skin plaque (psoriasis) or nail changes due to psoriasis.
- Your arthritis is active despite trying at least one standard treatment like NSAIDs or DMARDs (e.g., methotrexate).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This study is for people with psoriatic arthritis who have already completed a year-long treatment with zasocitinib or a similar medicine in a previous study. It tests whether continuing to take zasocitinib remains safe and helpful over a longer time.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
This study tests how well upadacitinib (a pill taken daily) works for people with active psoriatic arthritis that also affects the spine. It is for those who have not responded well enough to other treatments like NSAIDs or biologics.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.